Bisphenol A (BPA) is the monomer component of polycarbonate plastics and epoxy resins; human exposure derives from leachate in foodstuffs packaged in certain plastics or from epoxybased dental appliances. BPA (6) . Although it is almost entirely in its polymerized form, the BPA monomer finds its way into foodstuffs as a leachate of plastic packaging (7, 8) . Also, humans can be exposed to BPA from certain dental appliances (9,10). Because of its estrogenic activity, there is concern over human exposure to BPA.
Bisphenol A (BPA) is the monomer component of polycarbonate plastics. It behaves as a weak estrogen in classic bioassays, including cellular proliferation and cornification of the vaginal epithelium (1, 2) and pituitary prolactin secretion (3) in the ovariectomized rat, and it produces estrogen-like effects in rat mammary gland (4) and developing mouse prostate (5) . Nearly 2 billion pounds of BPA are manufactured annually in the United States (6) . Although it is almost entirely in its polymerized form, the BPA monomer finds its way into foodstuffs as a leachate of plastic packaging (7, 8) . Also, humans can be exposed to BPA from certain dental appliances (9, 10) . Because of its estrogenic activity, there is concern over human exposure to BPA.
When assessing the biologic activity of a putative estrogenic compound in animal model systems, it is important to consider species and strain differences. We previously found that BPA increased blood prolactin levels in Fischer 344 (F344) but not SpragueDawley (S-D) rats (3) . Such a finding is congruent with the earlier observation that estrogens stimulate growth of the pituitary through replication of the prolactin-secreting cells in F344 rats but not in outbred rat strains (11) (12) (13) . We also found that the uterine epithelium of F344 rats but not that of S-D rats exhibited a hypertrophic response to BPA administered in low doses (2) . These observations raise the question of whether there is a general difference between strains in responsiveness of estrogen target tissues to BPA.
The vaginal epithelium is a classic target tissue for studying the estrogenicity of a compound. Estrogens induce proliferation of the cells in the basal layer, thereby producing a multilayered, thick stratified epithelium; with continued estrogen stimulation the superficial layer of cells becomes keratinized (14) . More recently, it was shown that the immediate early genes, c-fos and c-jun, are induced by estrogen in target tissues (15) (16) (17) (18) . The induction of these genes is believed to play a key role in cell proliferation (19, 20) . In the present study, we determined the potency of BPA to induce immediate early gene expression and DNA synthetic activity in the vaginal epithelium of F344 and S-D rats.
Materials and Methods
Animals. All procedures performed on animals followed the NIH Guide for the Care and Use ofLaboratory Animals (21) Estrogen receptor assays. Vaginas from ovariectomized adult rats were homogenized and centrifuged to prepare a cytosol, as described previously (22) . Aliquots of the cytosol were incubated with increasing concentrations of [3H]estradiol (Amersham, Arlington Heights, IL) with or without a 100-fold molar excess of diethylstilbestrol (Sigma Chemical Company). Bound and free steroid were separated by the dextran-coated charcoal method (22) .
RNA isolation and RNase protection assaysfor c-fos. Total RNA was isolated from vagina by homogenizing the tissues in TriReagent (Molecular Research Center, Cincinnati, OH) according to the manufacturer's protocol. RNase protection assays (RPAs) were performed on 5 pg RNA from each specimen using a kit (RPA II; Ambion, Austin, TX) according to the manufacturer's instructions. We derived RNA probes from c-fos cDNA as described earlier by Nephew et al. (23) ; the plasmid was linearized with the restriction enzyme NcoI. Antisense riboprobes were generated from linearized templates using the MAXIscript kit (Ambion), T7 RNA polymerase, and 32P-uridine triphosphate (New England Nuclear, Boston, MA) according to the kit instructions. Cyclophilin mRNA levels were determined using riboprobe derived from the cDNA template pTRI-cyclophilin (Ambion). After incubation of RNA samples with the radiolabeled riboprobe and RNase, the protected riboprobe was separated on a polyacrylamide gel (6%). The gel was dried and exposed to X-ray film (Kodak X-Omat, Sigma Chemical Company). The X-ray film was analyzed on a GS-670 Imaging Densitometer (BioRad, Hercules, CA). The mRNA levels for cfos were normalized against the level of cyclophilin mRNA by dividing the optical density (OD) of the autoradiographic band for c-fos by the OD of the corresponding cyclophilin band ofeach specimen.
Statistical analysis. The number of BrdU-labeled cells per millimeter or the mRNA levels (arbitrary units of the OD ratios) were analyzed by analysis of variance (ANOVA) across all doses of BPA or E2, comparing the mean at each dose against the untreated control by Fisher's protected least significant difference (PLSD) test.
Results
In an earlier study (2) (Figure 2 ). It was also apparent that the maximal effect of BPA in F344 rats was approximately one-third of the maximal effect of E2 (compare Figures 1 and 2) . A simple explanation for the strain difference might be a difference in the rate of metabolic dearance of injected BPA. To test this, animals received an intravenous injection of 3H-BPA and the amount of radioactivity remaining in the blood was determined at various times thereafter, without regard to the proportions of parent compound or metabolite present. Disappearance of radiolabeled BPA was biphasic. After a rapid distribution phase, there was a sustained loss of compound exhibiting a half-life of approximately 90 min for each strain (Figure 3 ). In two of the animals, approximately one-half of the injected dose of radiolabel was found in the urine that remained in the urinary bladder at the end of 2 hr. Thus, there is a rapid clearance of BPA from the blood, and there does not appear to be any strain difference in this parameter.
The difference in sensitivity to BPA might be explained by a difference in the tissue (24) , responses typical of a partial estrogen. However, a 3-day treatment of ovariectomized rats with BPA caused the vaginal epithelium to become fully keratinized (1,2); this is the response of a full agonist. Also, prolactin secretion was increased to the same extent by estradiol or BPA, but pituitary growth was not induced (3) . Induction of c-fos expression by BPA reached a magnitude, and followed a timecourse, that would be expected for a natural estrogen (15) (16) (17) (18) . In a preliminary study, we also found that BPA induced expression of c-jun in both strains of rats, with steadystate levels reaching maximum at 2-3 hr after treatment (data not shown). Likewise, the time-course of the DNA synthetic response in the F344 vagina following a single injection of BPA is similar to that produced by natural estrogens (26, 27) . In studies on estrogenic effects in non-reproductive tissues, Dodge et al. (25) (2) . Thus, the biologic potency of this compound may depend on dosage, dosing schedule, and route of administration.
Biologic potency also depends on the metabolic clearance rate of a compound, and this may differ between the two strains of rats. To address this, we investigated the pharmacokinetics of a bolus injection of BPA. Knaak and Sullivan (29) showed that over the first 24 hr after BPA was administered orally to rats, > 80% of the administered material was excreted as a glucuronide in the urine or eliminated as free compound and a hydroxylated metabolite in the feces. Also, 8 days after administration, no BPA was detected in the animals (29) . In the present study, circulating BPA had a half-life of approximately 90 min. Although this simple analysis did not determine whether the radiolabel remaining in the blood was authentic starting material, it nonetheless indicates that there is a rapid clearance of BPA from the blood. Furthermore, the rate of clearance was similar in F344 and S-D rats, indicating that strain-specific metabolic clearance does not play a role in establishing the difference in the biologic responses. Further studies are required to determine additional pharmacokinetic parameters under the condition of a continuous administration regimen.
Our results show that the F344 inbred rat strain is more sensitive to BPA induction of DNA synthesis in vaginal epithelium than the outbred S-D rat strain. Furthermore, this strain difference appears to be specific to the weakly estrogenic compound BPA, as there was no difference between strains in sensitivity to E2 stimulation. Yet, the initial events that lead to the DNA synthetic response, ER binding and immediate early gene transcription, show no strain differences that account for the difference in sensitivity to BPA. Although BPA induced expression of immediate early genes in S-D rats, this expression was not sufficient to produce the proliferative response; this is similar to a single dose of either of the weak estrogens estriol or 16a-E2, which was able to induce expression of immediate early genes but did not induce the growth response in rat uterus (30, 31) . In a preliminary study, we found that three daily injections of estriol produced a uterine growth response and that this treatment was more effective in F344 rats than in S-D rats (32) .
Our observations suggest that the strain difference is due to a delayed, or intermediate, effect rather than a primary response mechanism. Lanahan et al. (33) described a set of "delayed early genes" whose expression is induced by growth stimuli, but only after several hours. Using a short-acting estrogen, 16u-E2, Stack and Gorski (34) showed that stimulation of DNA synthesis in the rat uterus is positively correlated to the rate of protein synthesis at 12 hr after an injection of estrogen. Cheng and Pollard (35) showed that uterine expression of c-rasH and ornithine decarboxylase increased 6-12 hr after estradiol treatment. Dean and Sanders (36) suggested that there are two classes of genes which respond to estrogenic stimuli in a delayed manner: the secondary response genes that are dependent on the products of the early primary response genes for their stimulation, and the delayed primary response genes that are dependent on a direct interaction of steroid receptor with the gene's promoter and concomitant enhancement by a product of the early primary response gene. It may be that the delayed response genes stimulated by E2 in both S-D and F344 rats are not induced by BPA in the S-D rat but are induced by BPA in the F344 rat; this possibility requires further investigation.
Strain differences in response to estrogenic stimuli have been previously demonstrated. Gorski and co-workers (11) (12) (13) found that the potent estrogens diethylstilbestrol or E2 induce an overgrowth of lactotropes in the pituitary glands of F344 rats but not in those of outbred strains of rats. Recently, Spearow et al. (37) found dramatic strain differences in the susceptibility of mice to estradiol-induced disruption of testicular development. Others have shown differences in the efficacy of E2 in stimulation of uterine DNA synthesis between strains of mice (38, 39) . Our data extend these observations to the vaginal response in rats and point out strain differences in sensitivity tO a weak estrogen, BPA. This type of difference must be taken into account when utilizing the classic vaginal response model for assessment of estrogenic activity of test compounds.
The genetic parameters that are responsible for strain differences in estrogen sensitivity or efficacy are largely unknown. However, Roper et al. (40) recently reported that several genetic quantitative trait loci may be partly responsible for the varied efficacy of E2 to induce uterine growth in different strains of mice. Similarly, Wendell and Gorski (13) identified five quantitative trait loci that genetically account for more than half of the difference between estrogen-induced growth of pituitary glands in F344 rats and Brown Norway rats, but these chromosomal loci do not correspond to those that account for strain differences in uterotrophic responses in mice (40) . At present, although a number of genes located within the quantitative trait loci are known, the specific genes responsible for these strain differences have not been identified (40) . There were no strain differences in estrogenic stimulation of several oncogenes or angiogenic factors in the pituitary gland; therefore, these genes are unlikely to mediate this effect (41). Similarly, we found that the immediate early genes c-fos and c-jun had no apparent role in establishing the strain difference to BPA stimulation in the vagina. Also, we have found that the ERs of each strain of rats have the same characteristic binding affinity and tissue concentration, ruling out alterations at this level as the simple explanation. As mentioned above, it may be that a later event, such as modulation of an intermediate gene, accounts for the strain differences. Identification of the genetic traits responsible for strain differences in sensitivity to the action of weak estrogens in rodents may yield valuable insight into the causes of varied susceptibilities to xenoestrogen action in humans.
